Press Releases

 
Press Releases
Date Title and Summary View
Nov 3, 2015 Total Revenues of $183.5 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.37 Myriad Completes Conversion of Targeted Physicians to myRisk™ Hereditary CancerCompany Maintains Fiscal Year 2016 Financial Guidance and provides Fiscal Second-Quarter 2016 Financial Guidance SALT LAKE CITY, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Myriad Gene...
Oct 28, 2015 SALT LAKE CITY, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 24th Annual Credit Suisse Healthcare Conference at 5:00 pm EST on November 11, 2015, at the Phoenician Resort in Phoenix, Arizona. The presentation will be ...
Oct 22, 2015 SALT LAKE CITY, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on Vectra DA will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) meeting being held Nov. 7-11, 2015 in San Francisco...
Oct 21, 2015 SALT LAKE CITY, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data on its myRisk™ Hereditary Cancer molecular diagnostic test will be featured in five presentations at the National Society of Genetic Counselors (NSGC) Annual Conferen...
Oct 20, 2015 SALT LAKE CITY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal first-quarter 2016 and provide a business update following the close of market on Tuesday, November 3, 2015. The Company also will host a conference call at 4:30 p.m. ET on November 3, 2015 to...
Oct 9, 2015 SALT LAKE CITY, Oct. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present new data on its myRisk™ Hereditary Cancer molecular diagnostic test at the 18th Annual Meeting of the Collaborative Group of the Americas - Inherited Colorectal...
Oct 8, 2015 SALT LAKE CITY, Oct. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new clinical outcomes and clinical utility data for myPath® Melanoma will be featured at the American Society of Dermatopathology (ASDP) 52nd meeting being held Oct. 8 to 11, 20...
Oct 7, 2015 SALT LAKE CITY, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostat...
Oct 5, 2015 SALT LAKE CITY, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that there will be seven poster presentations featured at American Society for Human Genetics (ASHG) meeting being held Oct. 6 to 10, 2015 in Baltimore, Md. "At Myriad, we are passion...
Oct 1, 2015 SALT LAKE CITY and ZURICH, Switzerland, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that Jan Schlüchter, Ph.D., has joined the Company as chief commercial officer (CCO) of Myriad Genetics GmbH, effective...
Page: FirstPrevious ...
7
... NextLast
= add release to Briefcase